For the research, doctors from hospitals across the UK, in collaboration with inhaler manufacturer Chiesi, examined 2,614 pressurised metered-dose inhalers (pMDIs) returned through a recycling scheme.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...